thenewsfacts.com
  • Home
  • Latest News
  • Trending News
  • Technology
  • entertainment
  • Sports
  • Business
thenewsfacts.comthenewsfacts.com
Font ResizerAa
Search
  • Home
  • Latest News
  • Trending News
  • Technology
  • entertainment
  • Sports
  • Business
Follow US
© thenewsfacts : All Rights Reserved.

Home » India’s Indigenous Cancer and Vaccine Research Enters Next Phase

Latest News

India’s Indigenous Cancer and Vaccine Research Enters Next Phase

TheNewsFacts
Last updated: July 21, 2026 5:19 pm
TheNewsFacts
Share
ICMR news
India’s Indigenous Cancer and Vaccine Research Enters Next Phase
SHARE

July 21, 2026: A cancer therapy candidate designed to target HPV-related precancerous lesions and two vaccine technologies against major enteric infections have moved one step closer to further development following technology transfer agreements facilitated by the Indian Council of Medical Research (ICMR).

Under its Medical Innovations Patent Mitra initiative, ICMR has licensed three indigenous biomedical technologies to Indian pharmaceutical and vaccine manufacturers, creating a pathway for research developed in public institutions to progress towards manufacturing, clinical development and wider healthcare application.

The technologies include SHetA2, a novel anti-HPV therapeutic candidate licensed to Emcure Pharmaceuticals Ltd., and two next-generation enteric vaccine candidates developed at ICMR–National Institute of Research in Bacterial Infections (ICMR-NIRBI), Kolkata, which have been licensed to Biological E Ltd.

The transfers represent an important stage in biomedical innovation: moving promising discoveries from research laboratories into structured development programmes where their safety, effectiveness and scalability can be evaluated.

A New Vaccine Approach Against HPV-Related Cervical Disease

SHetA2 represents a targeted approach to HPV-associated cervical disease, one of the leading causes of cervical cancer worldwide.

Developed through collaboration between ICMR-National Institute of Cancer Prevention and Research (ICMR-NICPR) scientist Dr. Showket Hussain and Dr. Doris M. Benbrook of the Stephenson Cancer Center, University of Oklahoma, USA, the candidate is designed to selectively eliminate HPV-induced precancerous and cervical cancer cells while limiting damage to healthy cells.

If successful through further development and clinical evaluation, such targeted therapies could offer alternatives to existing treatment approaches for cervical intraepithelial neoplasia (CIN), particularly in settings where access to advanced cancer care remains limited.

The development also aligns with wider efforts in cervical cancer control, where early detection, vaccination and improved treatment options are considered critical components of reducing disease burden.

Vaccine Research Targets Enteric Infections

Alongside the cancer therapy candidate, ICMR has transferred two vaccine technologies focused on bacterial infections affecting the gastrointestinal system.

Developed by Dr. Santasabuj Das and his team at ICMR-NIRBI, the candidates address diseases caused by enteric pathogens, including Salmonella typhi, which causes typhoid fever, as well as Shigella infections.

The technologies include a fusion construct using Salmonella typhi outer membrane protein as a potential next-generation typhoid vaccine candidate and a recombinant vaccine composition designed to provide broader protection against Salmonella typhi, paratyphi and Shigella infections.

These approaches are significant because enteric bacterial diseases continue to pose public health challenges, particularly due to antimicrobial resistance and the need for vaccines that provide broader and more durable protection.

Building a Research-to-Market Pipeline

The latest transfers highlight a growing focus on converting publicly funded biomedical research into products that can reach healthcare systems.

According to Dr. Rajiv Bahl, Secretary, Department of Health Research (DHR) and Director General, ICMR, initiatives such as Medical Innovations Patent Mitra are intended to strengthen collaboration between researchers and industry by supporting patent protection, licensing and commercial development.

India’s biomedical research ecosystem has increasingly focused on creating stronger links between discovery science, intellectual property management, regulatory pathways and manufacturing capabilities.

The challenge ahead will be translating these technologies through rigorous clinical evaluation, regulatory approvals and large-scale production while maintaining affordability and accessibility.

Where This Could Lead

The transfer of these technologies signals a broader shift in India’s healthcare innovation landscape—from primarily adopting medical solutions developed elsewhere to building and scaling homegrown technologies.

For cancer therapeutics, advances such as targeted molecular approaches could complement existing prevention and treatment strategies. For infectious diseases, locally developed vaccines could strengthen preparedness against endemic pathogens and support broader public health programmes.

The next phase will depend on clinical progress, manufacturing readiness and successful deployment. If these technologies move through development successfully, they could add to India’s growing portfolio of indigenous biomedical solutions serving both domestic and global healthcare needs.

TAGGED:Biomedical ResearchBiopharmaBiotechnologyCancer ResearchCervical CancerEnteric Vaccineshealthcare innovationHPV TherapyICMRInfectious DiseasesMedical Innovations Patent MitraSHetA2Shigella vaccineTyphoid Vaccinevaccines
Share This Article
Email Copy Link Print
Previous Article Skyroot vikram 1 Skyroot’s Vikram – 1 Orbital Success Opens New Opportunities
Next Article SHITIJ 2.0 ICAR Opens SHITIJ 2.0 to Turn Farm Innovations Into Startups

Your Trusted Source for Accurate and Timely Updates!

We're committed to providing accurate and unbiased news as it unfolds, earning the trust of a large audience. Stay informed with our news updates on the latest events and trends, keeping you ahead of the curve.
FacebookLike
XFollow
InstagramFollow

Popular Posts

Fortnite Epic Games Battle Royale Now on Maintenance Mode

Fortnite Epic Games' smash hit Battle Royale is offline and inaccessible to play as it shifts…

By
TheNewsFacts

Is it time for Amitabh Bachchan to Retire, Or?

Amitabh Bachchan the legendary actor, who is all over the media, whether it is movies,…

By
TheNewsFacts

Federer – Djokovic Deserves to stand on the brink of history

The 18th time on Saturday and then admitted that overwhelming title favourite "deserves" to stand…

By
TheNewsFacts

You Might Also Like

Tragedy King of Indian Cinema Dilip Kumar No More
Latest NewsEntertainment

Tragedy King of Indian Cinema Dilip Kumar No More

By
TheNewsFacts
COVID-19 Survey, US reports 53% mental ailment in Public Health workers
COVID-19Latest News

COVID-19 Survey, US reports 53% mental ailment in Public Health workers

By
TheNewsFacts
Meenakshi Alternates
BusinessLatest News

Meenakshi Group Unveils Rs. 700Cr “Meenakshi Real Assets Fund”

By
NewsFacts Bureau
Now, UAE suspends Indian wheat exports for 4 months
Latest News

Why UAE suspended Indian wheat exports?

By
TheNewsFacts
thenewsfacts thenewsfacts

About US


TheNewsFacts: Brings you the interesting facts, news facts and updates from India an the world across politics, tech, entertainment, business, tending, and more. We deliver what you love to read.
Top Categories
  • Latest News
  • Trending News
  • Paris Olympics 2024
  • Sports
  • Entertainment
  • Business
  • Technology
Usefull Links
  • About The News Facts
  • Latest News
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Contact Us
Follow us
Facebook Twitter Instagram

© thenewsfacts. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?